As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2025 about Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products can be found below.